MedTrace Logo

Liraglutide for Low-responders After Bariatric Surgery

NCT04643301 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-04-26

No results posted yet for this study

Summary

To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.

Conditions

Interventions

DRUG

Liraglutide Pen Injector

Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.

Sponsors & Collaborators

  • Nederlandse Obesitas Kliniek

    collaborator UNKNOWN

  • Zuyderland Medisch Centrum

    lead OTHER

Principal Investigators

  • J.W. Greve, MD, PHD · Nederlandse Obesitas Kliniek/Zuyderland Medisch Centrum

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2021-12-31
Completion
2021-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04643301 on ClinicalTrials.gov